Introduction Adoptive cellular immunotherapies have transformed cancer treatment, but current strategies generally require ex vivo cell engineering, manufacturing complexity and individualized processing. The ability to selectively reprogram cytotoxic effector CD8 T cells directly in vivo represents a major next frontier in immunotherapy and RNA-based medicine.
Introduction
Adoptive cellular immunotherapies have transformed cancer treatment, but current strategies generally require ex vivo cell engineering, manufacturing complexity and individualized processing. The ability to selectively reprogram cytotoxic effector CD8 T cells directly in vivo represents a major next frontier in immunotherapy and RNA-based medicine.
Problem Statement
Existing lipid nanoparticle (LNP) platforms lack precise targeting specificity for cytotoxic effector T-cell subsets, limiting their ability to selectively manipulate immune responses in vivo. Developing efficient, transient and clinically scalable approaches for targeted CD8 T-cell reprogramming remains a critical unmet challenge in immunotherapy.
Summary
This study introduces a highly innovative ligand-directed mRNA-LNP platform capable of selectively targeting CX3CR1-positive cytotoxic effector CD8 T cells in vivo using fractalkine (CX3CL1)-conjugated nanoparticles. By exploiting the natural interaction between fractalkine and the CX3CR1 receptor expressed on effector T cells, the investigators achieved remarkably efficient and selective mRNA delivery in both murine models and nonhuman primates. In mice, fractalkine-conjugated mRNA-LNPs targeted up to 95% of circulating and splenic effector CD8 T cells, enabling successful transient cellular reprogramming. Delivery of IL-2–encoding mRNA induced robust exogenous IL-2 secretion, while CD62L-encoding mRNA restored lymphoid homing receptor expression on differentiated effector cells. Importantly, the platform demonstrated impressive translational potential in rhesus macaques, where nearly all peripheral effector CD8 T cells were successfully targeted and reprogrammed to express human CD62L, including trafficking into lymphoid tissues. The work establishes proof-of-concept that endogenous immune cells can be rapidly modified in vivo without ex vivo manipulation or viral engineering. The transient nature of mRNA expression may also offer important safety advantages compared with permanent genetic modification approaches. Beyond oncology, this platform may have broad applications in infectious disease, vaccine development, autoimmunity and immune modulation. Overall, the study represents a major advance in targeted RNA therapeutics and demonstrates the feasibility of highly selective in vivo immune-cell engineering using receptor ligand–guided mRNA nanoparticle technology.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.